MW-ATTC team speak at Advanced Therapy Adoption workshop

19 November 2018

Key members of the Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC) recently attended a national event exploring how the ATTC network can drive the adoption of advanced cell and gene therapies into the NHS for the benefit of patients.

Nisha Sungum, MW-ATTC Programme Manager, was part of a panel discussion at the workshop event, hosted by Cell and Gene Therapy Catapult in collaboration with the UK BioIndustry Association and the Association of the British Pharmaceutical Industry (ABPI), on 19 September 2018.

“This was the first workshop to feature stakeholders across the entire national network, bringing together a wealth of expertise to ensure these innovative therapies benefit NHS patients,” said Nisha.

“The collaboration between the NHS and industry means the UK will be leading the world in the use of advanced therapies and treatments that have the potential to change patients’ lives.”

Cell and gene therapies are showing great potential across a range of disease areas, but the complexity involved in adopting these therapies into routine practice requires new systems to be created.

“The ATTC network will work together with its partners to address the priorities addressed at the workshop, to promote better patient access to advanced therapy medicinal products,” added Keith Thompson, Chief Executive Officer of the Cell and Gene Therapy Catapult.

The national ATTC network – including the MW-ATTC, Innovate Manchester Advanced Therapy Centre Hub (iMATCH), and Northern Alliance Advanced Therapies Treatment Centre (NAATTC), in collaboration with the London Advanced Therapy Network – aims to develop easily-run solutions that can be rolled-out across the NHS, ensuring the treatments can reach increasing numbers of patients.

The ATTC network was awarded funding by Innovate UK, through the Industrial Strategy Challenge Fund.

Attendees at the workshop included NHS staff, pharmaceutical companies, supply chain providers and regulators such as NICE, NHS Wales, NHSE and MHRA representatives.

Key topics at the event included data sharing considerations, the importance of involving patients in development, re-imbursement, and planning and infrastructure investment to ensure the potential of cell and gene therapies for transformative patient care is met.

A video, taken at the event, can be viewed here.